Arrowhead Pharmaceuticals (NASDAQ:ARWR) Raised to Sell at StockNews.com

StockNews.com upgraded shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) to a sell rating in a report published on Thursday morning.

A number of other research firms also recently issued reports on ARWR. Royal Bank of Canada reaffirmed an “outperform” rating and set a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Thursday, September 26th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arrowhead Pharmaceuticals in a report on Monday, September 9th. Piper Sandler reaffirmed an “overweight” rating and set a $62.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, October 8th. Chardan Capital restated a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, July 17th. Finally, HC Wainwright reissued a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Friday, October 11th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $45.33.

Arrowhead Pharmaceuticals Price Performance

Shares of NASDAQ:ARWR opened at $21.18 on Thursday. The firm has a fifty day moving average price of $21.35 and a two-hundred day moving average price of $23.93. Arrowhead Pharmaceuticals has a one year low of $17.05 and a one year high of $39.83. The company has a market cap of $2.63 billion, a price-to-earnings ratio of -4.98 and a beta of 0.95.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.80). During the same period in the prior year, the company earned ($0.96) EPS. The firm’s quarterly revenue was down 100.0% compared to the same quarter last year. Equities research analysts expect that Arrowhead Pharmaceuticals will post -4.31 EPS for the current fiscal year.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. Buffington Mohr McNeal purchased a new stake in Arrowhead Pharmaceuticals in the 3rd quarter worth approximately $581,000. Handelsbanken Fonder AB lifted its holdings in Arrowhead Pharmaceuticals by 17.0% in the 3rd quarter. Handelsbanken Fonder AB now owns 35,700 shares of the biotechnology company’s stock worth $692,000 after buying an additional 5,200 shares during the period. SG Americas Securities LLC lifted its stake in shares of Arrowhead Pharmaceuticals by 275.8% in the 3rd quarter. SG Americas Securities LLC now owns 35,206 shares of the biotechnology company’s stock valued at $682,000 after purchasing an additional 25,837 shares during the period. Quarry LP lifted its stake in shares of Arrowhead Pharmaceuticals by 54.5% in the 2nd quarter. Quarry LP now owns 8,500 shares of the biotechnology company’s stock valued at $221,000 after purchasing an additional 3,000 shares during the period. Finally, Creative Planning lifted its stake in shares of Arrowhead Pharmaceuticals by 9.4% in the 2nd quarter. Creative Planning now owns 28,276 shares of the biotechnology company’s stock valued at $735,000 after purchasing an additional 2,420 shares during the period. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.